Expanded Access to Provide Selitrectinib for the Treatment of Cancers With a NTRK Gene Fusion

Solid Tumors Harboring NTRK Fusion Clinical Trial

Official title:

Expanded Access to Provide Selitrectinib (BAY2731954) for the Treatment of Cancers With a NTRK Gene Fusion.

Clinical Trial Details — Status: No longer available

Administrative data

• NCT number: NCT03206931
• Other study ID #: 21002
• Status: No longer available

Study information

• Verified date: September 2021
• Source: Bayer
• Contact: n/a
• Is FDA regulated: No
• Study type: Expanded Access

Clinical Trial Summary

Selitrectinib expanded access is for minor and adult patients with cancer having a change in a particular gene (NTRK1, NTRK2, or NTRK3 gene fusion). The patients are ineligible for an ongoing selitrectinib clinical trial or have other considerations that prevent access to selitrectinib through an existing clinical trial. Expanded access is intended to treat individual patients with different types of cancers with a NTRK gene fusion, including blood cancers, who have previously received tropomyosin receptor kinase (TRK) inhibitor therapy.

Recruitment information / eligibility

• Status: No longer available
• Enrollment: 0
• Gender: All
• Age group: 1 Month and older

Eligibility

Inclusion Criteria:

• Diagnosis of cancer with a NTRK1, NTRK2, and NTRK3 gene fusion
• Previous treatment with a kinase inhibitor with known activity on TRK inhibition
• Unable to participate in an ongoing selitrectinib clinical trial
• Medically suitable for treatment with selitrectinib

Exclusion Criteria:

• Currently enrolled in an ongoing clinical study with a TRK inhibitor

Related Conditions & MeSH terms

• Solid Tumors Harboring NTRK Fusion

Intervention

Drug:
• Selitrectinib (BAY2731954)
Selitrectinib is administered as capsules or liquid formulation.

Locations

Country	Name	City	State
n/a

Sponsors (1)

Lead Sponsor	Collaborator
Bayer